Inventor · disambiguated record
Bibia Heidmann
Also filed as: HEIDMANN BIBIA
21 granted patents·74 citations·filing 2011–2021
94Inventor score
Files withIDORSIA PHARMACEUTICALS LTD12ACTELION PHARMACEUTICALS LTD3AISSAOUI HAMED2BOLLI MARTIN2BOSS CHRISTOPH2
Top patents by PatentIndex Score
21 records- 0187US9732075B2Benzimidazole-proline derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2013·Granted Aug 15, 2017·8 cites·12 claims
- 0286US11059803B2Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamideIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Jul 13, 2021·2 cites·12 claims
- 0385US10065929B2Pyrazole compounds and their use as T-type calcium channel blockersIDORSIA PHARMACEUTICALS LTD·Filed 2017·Granted Sep 4, 2018·5 cites·30 claims
- 0484US10329287B2Benzimidazole-proline derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2017·Granted Jun 25, 2019·3 cites·12 claims
- 0584US9932314B2Pyrazole compounds and their use as T-type calcium channel blockersIDORSIA PHARMACEUTICALS LTD·Filed 2015·Granted Apr 3, 2018·5 cites·28 claims
- 0684US9150566B22-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonistsBOLLI MARTIN·Filed 2012·Granted Oct 6, 2015·7 cites·27 claims
- 0783US10023560B2Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonistIDORSIA PHARMACEUTICALS LTD·Filed 2017·Granted Jul 17, 2018·3 cites·13 claims
- 0883US9211279B2Proline sulfonamide derivatives as orexin receptor antagonistsACTELION PHARMACEUTICALS LTD·Filed 2015·Granted Dec 15, 2015·3 cites·30 claims
- 0982US10246426B2Triazole compounds as T-type calcium channel blockersIDORSIA PHARMACEUTICALS LTD·Filed 2015·Granted Apr 2, 2019·5 cites·13 claims
- 1082US9493446B2Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivativesACTELION PHARMACEUTICALS LTD·Filed 2013·Granted Nov 15, 2016·6 cites·21 claims
- 1181US9790208B2Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonistIDORSIA PHARMACEUTICALS LTD·Filed 2014·Granted Oct 17, 2017·4 cites·6 claims
- 1281US8895606B2Proline sulfonamide derivatives as orexin receptor antagonistsBOSS CHRISTOPH·Filed 2011·Granted Nov 25, 2014·5 cites·9 claims
- 1380US9000029B2Proline sulfonamide derivatives as orexin receptor antagonistsBOSS CHRISTOPH·Filed 2014·Granted Apr 7, 2015·4 cites·13 claims
- 1478US9914720B2Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonistsIDORSIA PHARMACEUTICALS LTD·Filed 2014·Granted Mar 13, 2018·3 cites·12 claims
- 1578US9914721B2Use of benzimidazole-proline derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2014·Granted Mar 13, 2018·4 cites·14 claims
- 1675US9242970B2Lactam derivatives useful as orexin receptor antagonistsAISSAOUI HAMED·Filed 2011·Granted Jan 26, 2016·3 cites·12 claims
- 1772US8889688B2Piperazines as antimalarial agentsAISSAOUI HAMED·Filed 2011·Granted Nov 18, 2014·2 cites·36 claims
- 1871US11040966B2Benzimidazole-proline derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2019·Granted Jun 22, 2021·0 cites·29 claims
- 1969US11555025B2Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2- [4-(1-trifluoromethyl-cyclopropyl)-phenyl-acetamideIDORSIA PHARMACEUTICALS LTD·Filed 2021·Granted Jan 17, 2023·0 cites·2 claims
- 2068US9403813B2Azetidine amide derivatives as orexin receptor antagonistsACTELION PHARMACEUTICALS LTD·Filed 2014·Granted Aug 2, 2016·1 cites·12 claims
- 2168US9303023B2Pyrazole and imidazole derivatives useful as orexin antagonistsBOLLI MARTIN·Filed 2012·Granted Apr 5, 2016·1 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Bibia Heidmann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →